MATTHEW GILL: Open Payments
NPI 1114251238 · COLLINSVILLE, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$515 in 31 payments from 15 companies in 2025. Trend: 2023 $84 · 2024 $270 · 2025 $515
Food & beverage: $515
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $91 |
| Lilly USA, LLC | 6 | $89 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Novo Nordisk Inc | 2 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $26 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
Products named: MOUNJARO, VRAYLAR, CAPLYTA, Kerendia, TRINTELLIX, Ozempic, XIFAXAN, LINZESS.
Industry payments across OK — which companies pay providers there.
